HHS Unveils Strategy to Accelerate US Drug Discovery, Stemming Clinical Trial Shift to China

June 28, 2026

BioPharma Dive USA

Overview

The U.S. Department of Health and Human Services (HHS) has launched a comprehensive initiative to accelerate early-stage drug research domestically, directly countering the recent trend of clinical trials migrating to China. A new pilot program will incentivize pharmaceutical companies to conduct initial clinical trials within the U.S., specifically aiming to significantly reduce the timeline from drug candidate identification to first-in-human (FIH) studies. This strategic move seeks to enhance U.S. biopharmaceutical competitiveness and ensure faster delivery of innovative treatments to patients.

In Depth

Background

The global pharmaceutical landscape has seen a notable shift in recent years, with a growing number of clinical trials, particularly in biopharmaceuticals, relocating overseas. China has emerged as a primary destination for these studies, driven by factors such as lower operational costs, access to diverse patient populations, and perceived regulatory flexibility. This migration has raised concerns within the U.S. government regarding its potential impact on the nation’s biopharmaceutical industry competitiveness and its readiness to respond to future public health crises, including pandemics. In response, the U.S. Department of Health and Human Services (HHS) has identified the need to fortify the domestic research and development ecosystem and foster innovation within its borders.

Key Findings

To address these strategic concerns, the HHS has unveiled a comprehensive set of reforms designed to accelerate early-stage drug research within the United States. A central component of this initiative is a new pilot program specifically structured to encourage pharmaceutical companies to conduct their initial clinical trials on U.S. soil. The program targets the critical phase from drug candidate identification to the First-in-Human (FIH) study, aiming to significantly reduce the regulatory and procedural timelines associated with this stage. By streamlining these processes, HHS expects to expedite the entire drug development cycle. Furthermore, HHS is actively reviewing the legal and ethical implications of offering financial incentives to clinical trial participants. Such a policy, if implemented, could substantially improve patient recruitment, particularly for studies requiring diverse cohorts, thereby enhancing both the speed and quality of clinical investigations.

Significance & Outlook

These HHS reforms are poised to exert a profound impact on the U.S. drug discovery ecosystem. The acceleration of early-stage clinical trials means that promising drug candidates can advance more rapidly into full clinical development, ultimately shortening the time it takes for new and potentially life-saving medications to reach patients. Should the proposed legalization of participant payments materialize, it would significantly ease the recruitment of diverse patient populations, further improving the efficiency and robustness of clinical trials. This strategic reorientation is expected to re-establish the United States as a leading global hub for clinical research, securing its competitive edge in biopharmaceutical development against rising international contenders like China.

Source: https://www.biopharmadive.com/news/hhs-clinical-trial-streamline-plan-china/823504/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.